Lung Cancer Screening: Reduced Mortality in Never-Smokers & Beyond

Lung cancer screening with low-dose CT (LDCT) scans may significantly reduce mortality even in individuals who have never smoked, particularly in Asian populations, according to data presented at the European Lung Cancer Congress (ELCC) 2026. The findings challenge current screening guidelines, which primarily target longtime or heavy smokers, and suggest a broader approach to lung cancer detection could save lives.

The research, stemming from the LUNG-CARE Project, a prospective, interventional, nonrandomized study of a Chinese cohort, demonstrated a hazard ratio of 0.45 (95% CI, 0.32-0.65; P<0.001) for death due to lung cancer among those screened with LDCT compared to a control group who did not undergo screening. The study followed patients for a median of seven years.

“Current screening guidelines were built around smoking history, and in doing so, they leave behind a large and growing group of people who develop lung cancer despite never having smoked,” explained Dr. Marina Garassino of the University of Chicago, who was not involved in the study. This observation highlights a critical gap in current preventative measures, as the incidence of lung cancer among never-smokers is increasing globally.

Distinct Epidemiological Characteristics in Asia

The study authors emphasized that the distinct epidemiological characteristics of lung cancer in Asian populations warranted further investigation into the benefits of LDCT screening in non–risk-based populations. Lung cancer in Asia often presents differently than in Western countries, with a higher proportion of cases occurring in individuals who have never smoked, and a greater prevalence among women and those exposed to environmental factors.

Dr. Caichen Li presented the LUNG-CARE Project data at the ELCC 2026, noting that while the efficacy of LDCT scanning is “established in selected populations in Western countries,” the unique factors at play in Asia necessitate a reevaluation of screening strategies.

Sex-Specific Reductions in Mortality

The benefits of LDCT screening were observed across both sexes, although the reduction in mortality was more pronounced in women. Lung cancer screening was associated with reduced mortality in men (HR, 0.55; 95% CI, 0.36-0.83; P=0.004) and even more significantly in women (HR, 0.28; 95% CI, 0.13-0.60; P<0.001).

These findings align with recent research indicating that never-smokers are a rapidly growing group affected by lung cancer. A study highlighted by Medical Xpress in March 2026 noted that most current screening programs focus on smokers, overlooking this expanding population. The ESMO (European Society for Medical Oncology) also reported on the study, emphasizing the need to adapt guidelines to account for the unique epidemiological landscape of lung cancer in Asia.

Implications for Global Screening Programs

The LUNG-CARE Project’s results suggest that a population-based approach to lung cancer screening, rather than solely targeting high-risk individuals based on smoking history, could significantly reduce mortality rates. This is particularly relevant in regions like Asia, where a substantial proportion of lung cancer cases occur in never-smokers.

One-time low-dose CT screening may be sufficient to reduce mortality among never-smokers in Asia, according to reporting from The ASCO Post. This finding could have significant implications for resource allocation and the implementation of widespread screening programs.

While the study was not randomized, the use of a naturally occurring control cohort from the same geographic region and age range strengthens the validity of the findings. Further research, including randomized controlled trials, will be crucial to confirm these results and refine screening protocols for never-smokers globally.

The findings underscore the importance of considering regional variations in lung cancer epidemiology when developing and implementing screening programs. As the incidence of lung cancer among never-smokers continues to rise, adapting screening strategies to include this vulnerable population will be essential to improving outcomes and reducing the burden of this devastating disease.